Analysts initiate coverage on Alumis and Enliven with bullish ratings
Summary: Baird analyst Brian Skorney has started coverage on Alumis Inc. with an Outperform rating and a price target of $25. The stock closed at $11.23 on Wednesday.
Jones Trading analyst Soumit Roy also initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $36, while the stock closed at $28.39.
Other analysts began coverage on Intensity Therapeutics, Terns Pharmaceuticals, and Braze, with varying ratings and price targets reflecting their current stock prices.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings